-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LQLo44b8gD0BhJdGgaLf0r3sqCuE1MdbGQFBFqQgQ7aKnCCazET8aH2eOi/McOq/
 pEvFaCHmYapyHe6bpFY2/A==

<SEC-DOCUMENT>0001144204-08-050173.txt : 20080828
<SEC-HEADER>0001144204-08-050173.hdr.sgml : 20080828
<ACCEPTANCE-DATETIME>20080827202614
ACCESSION NUMBER:		0001144204-08-050173
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080827
FILED AS OF DATE:		20080828
DATE AS OF CHANGE:		20080827

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		081043220

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v125088_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      month of August 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      &#160;XTL Biopharmaceuticals Ltd.&#160;&#160;&#160;&#160; &#160;&#160;&#160;
&#160;&#160;&#160; </u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x&#160;
</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o&#160;
</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>&#160;&#160;
      N/A&#160; &#160;</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
      by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated August 27,
      2008
      is hereby incorporated by reference into the registration statements on Form
      F-3
      (File No. 333-141529, File No. 333-147024 and File No. 333-135055) filed by
      XTL
      Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March
      23,
      2007, October 30, 2007 and August 15, 2008, respectively, and the registration
      statements on Form S-8 (File No. 333-148058 and File No. 333-148574) filed
      by
      XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on
      December 14, 2007 and January 18, 2008, respectively.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
<IMG SRC="logo.jpg">
</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Notification
      of Extraordinary General Meetings and Further Changes to Board
      Composition</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, August 27, 2008 </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
      XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced a notice
      convening two Extraordinary General Meetings (the &#8220;Meetings&#8221;). The Meetings will
      take place at the Conference Room at the Company&#8217;s Israeli offices at Building
      3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 3:00 p.m. Israel
      time, and 5:30 p.m. Israel time, respectively, on October 2, 2008. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
      the
      first Extraordinary General Meeting it is proposed that: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Kenneth
                J. Zuerblis, Chief Financial Officer of Imclone Systems, Inc. (NASDAQ:
                IMCL), be and is hereby appointed as an External Director of the
                Company
                until October 2, 2011; and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jennifer
                L. Good, President and Chief Executive Officer of Penwest Pharmaceuticals
                Co. (NASDAQ: PPCO), be and is hereby appointed as an External Director
                of
                the Company until October 2, 2011</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
      the
      second </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Extraordinary
      General Meeting, which will follow the first Extraordinary General
      Meeting,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      it is
      proposed that the remuneration items of the directors as detailed in the Notice
      be approved.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Notice of the Meetings is available for the public at the US Securities Exchange
      Edgar site: http://www.sec.gov/ and at the Israel Securities Authority's site:
      www.magna.isa.gov.il.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      addition, Laurence N. Charney has notified the Company of his resignation from
      the Board of Directors effective today, August 27, 2008.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of diabetic neuropathic pain and HCV. XTL is developing
      Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
      of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has
      out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL
      also has an active in-licensing and acquisition program designed to identify
      and
      acquire additional drug candidates. XTL is publicly traded on the NASDAQ and
      Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="left">
      <table border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="justify" valign="top" width="48%">&#160;</td>
            <td align="justify" colspan="3" valign="top" width="52%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
                BIOPHARMACEUTICALS LTD.</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="48%">&#160;</td>
            <td align="justify" valign="top" width="4%">&#160;</td>
            <td align="justify" valign="top" width="33%">&#160;</td>
            <td align="justify" valign="top" width="15%">&#160;</td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="48%">&#160;</td>
            <td align="justify" valign="top" width="4%">&#160;</td>
            <td align="justify" valign="top" width="33%">&#160;</td>
            <td align="justify" valign="top" width="15%">&#160;</td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="48%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                August 27, 2008</font></div>
            </td>
            <td align="justify" valign="top" width="4%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:
                </font></div>
            </td>
            <td align="justify" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/
                Ron Bentsur</font></div>
            </td>
            <td align="justify" valign="top" width="15%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="top" width="48%">&#160;</td>
            <td align="left" valign="top" width="4%">&#160;</td>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
                Bentsur </font></div>
            </td>
            <td align="left" valign="top" width="15%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="top" width="48%">&#160;</td>
            <td align="left" valign="top" width="4%">&#160;</td>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Executive Officer</font></div>
            </td>
            <td align="left" valign="top" width="15%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0W+17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P.#HP.#HR
M-R`Q.3HU-3HU,````````Z`!``,````!``$``*`"``0````!````FJ`#``0`
M```!````-@`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```R5````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`-@":`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]524;38*WFIK7V!IV-<2UI='M:][6V.8
MW=^?Z=BX*W_&J[&S7XF;TEU+J;35D;<@/<TM=LMV-]%E=KF1_I??_I%)BP9,
MM\`XN'?4+9Y(PKB-6];F?6/H6#F,P<O.IIR7S^C>X#;#19^G=]#'W,=^C]=U
M?J_X):2\QZY]1>K]:ZP>J=,N9D8'5/UBK(OL<#6QS&6,;:QU;;?3]WI8M=5=
MWI4^GZWIKHOK)]<:?JG]BZ<*G]1N-(+W6VEMFQL5576V^C8VZR]S+M__`!?_
M``BEER\3[<<4O<R2%SC^[7_16#*1Q&8X8@^D]WK$EQ^']?KLGZO9_73TWTZ<
M%]=;&>N#ZCWN8RUN[T0ZKT6W4O\`YO\`2;UD_P#CO?\`FI_]F/\`WV0')YY6
M!"^$\)]4?F^;]Y)SXQ5RW%C0OHR2\Y_\=[_S4_\`LQ_[[)?^.]_YJ?\`V8_]
M]D?N/,_N?\Z'_?(^\8OWOPD^C)+SG_QWO_-3_P"S'_OLN]Z;F?;^G8N=L]/[
M537=Z<[MOJ-;9LW0W=MW?NJ/+R^7$`9QX;VUB?\`HKH9(3TB;ILI)+-_;'^6
M/V7Z/_7=W\CUOH;?[/TTR$)3XN$7PQ,Y?W8[HRYL>+@XSP^Y,8H:$\62?RQ]
M+I))))K(I)9/5NO?LW);1Z'J[F!^[?MY+FQ&Q_[BUD^6.<8QE(5&?R^-,6/F
M,62>3'"5SPD#(*(X>+Y5))))C*I))))3_]#U5>;_`.-'ZN-8YG7\9KB;'"K.
MU)$PUF-?MVEM;=K/0L]__<;V>I98O2$+)QZ<K'MQ;V[Z;V.KM9)$L>-CV[F[
M7?1<I<&8XL@F/*0_>BLR0$XF/V>;YQ]1_KKB]+Z!F8>>]N_!:Z[!K)VFT//]
M%9LK=[OM+MV]WJ?TC_08RYC$QNI_6WZPD>YU^9;ZF18T%S:JR1OL_2/_`)C&
MK]E5;K?]%CL_,6;G45XV;D8]5K<BNFU];+VQML:UQ8VUFUSV[;&C?]->I_XL
M^D=/QNC'J-5E63F93BVVU@.ZIHV_J3M_N:YKOTMOLK]3?7_/55X]RU,W!R\9
MYH#UY=NUG^7&U(<60QQD^F#T`^K_`$H]$9T.RKU,!C&,-<["[86V>H]U'H_I
M'VM]6US/YRQ9W_C>?4__`,K_`/P:_P#]++HTEDC-D%\,Y1LV:D1ZFX81.\0:
MTU#\Z+VC_P`;SZG_`/E?_P"#7_\`I9>+KZ+6E\1R3A[?!*4;XKX3P_NM7E8Q
MEQ6`=MP^`];QZ<7K.?BT-V4T9-U=3))AC+'L8W<[<[Z+5[9]6_\`Q.]+_P#"
M>/\`^>F+Q?ZR?^*+JG_AS(_\^O7M'U;_`/$[TO\`\)X__GIB;\0UPXOY?HIY
M;YYNDN;_`/6Q_P!?]`ND7']7INO^L-M-!(LM+&`B>'5L:_=M_,V?SG\A5^2C
MQ2RQ)J\4Q?:^%K_%YF&/EYB/$8\SCD(C>7")^EU,CZU8E5WIUU.M:UQ;99(`
M@&-]4;_5_P#`UHX'5,/J#-U#X>)W5.@/`'YVR3[=?I*=?3\&JHTLHK%;@`YN
MT'=M^AZD_P`YM_EKG>I>GT?KE5N-NKJ>UK[6-B-I<YMM;&GV[7-9]']]&$,&
M:X8XRA,`F,B>+CK][]U&7-SG*<.;/DAEPRD(SA&/`</%UQR_3_PW4ZMU#I.+
MDMKS<;U[2P.#O38^&RX;=UC@[Z06JYS6-+WD-:T2YQT``Y)*Y3ZV?\HU_P#$
MM_ZJQ7/K5E/(HP*I+K3O>QH,G7;2W3Z6Y^_V?R$?NPG'EP"1[@D9$ZB(BL'/
MG%/GI2C$C!+'''&(X99)9.(",I?I),KZUX59VX];KR"/<?8TB/S2X.?_`.!J
M[T_K.#GDMJ<66`P*[(#CINW,`<[>I]-Z7B]/J#:VAUL>^XCW.GG^JSV_S:QO
MK%TNK&:S/PVFES7-#VUB&C]RYNW^:]S=J$8\MDE[41*).D,A/%Q2_K079,GQ
M#!C^\9)8\D1ZLO+QCP>W#_5Y?TN%Z5)5\#*&7A4Y`B;&@N@$`.'ML:-W[K]R
ML*KP2X^"O5?#7];9T?=A[7NW^KX?<XOZE<?$_P#_T?55R?\`C"^LO[(Z4<3$
MN]/J69`9L=%E=7^%R/HNV[MOH5_S3_?ZM']'756V-JK?8X.+6-+B&M+W0!/L
MKK#K+'?R&-7C?7,+ZV?6+K+\RWI676Z]S:Z:G5V!E;![*Z_5N:VNMO\`A+;/
MT57J>K=^C5KD\49Y.*9`A#77J>@8<\S&-1OBEIHU.A_53J/6\'/S<71F"R6-
M+7$W6?3=CT;&N_2>DW_MQ^/7_A_5KO\`U!^M#NB]3&+DO=^SLQP8]I<`RNQQ
M:UF6?4]K6M;[+_?7^B_2?I/0J8O4^A]&Q>B],IZ?C-:!6T&VP"#99`]6]\E[
MMUCA^_\`H_YK^;K7FOUW^IF;B]9==T?!MMPLIOJ-9C5N>VIX]MU6VOU',;N_
M35^VJO\`2^C3_,*W#F8<Q+)BGI"7\W?A_P!U^FPRQ2QB,X_,/F?64ERWU!ZA
MU6SI@Z;U;$R,:_":&T66T/J8^AH:RMGJN:*W7T_0_,WU>G_._IWKJ5FY(&$S
M$FZZCJVHRX@#W?G1?1:\%_YM_6+_`,J\S_V'M_\`(+WI7OB<HGVZ(/S;?X+7
MY0$<=BMGP7ZR?^*+JG_AS(_\^O7M'U;_`/$[TO\`\)X__GIB\F^L'U?Z]=U[
MJ5M73<NRNS+O<Q[:+"US38]S7L<UFUS7-5#_`)M_6+_RKS/_`&'M_P#(*?-B
MAGQXX^X(<(!_>Z?WF.$Y8Y2/"3;[TN:<YK?KA+B&B0).FIIVM']IR\J_YM_6
M+_RKS/\`V'M_\@NR^K'1.L?8\6EV/;B6@O.^UCZ]I#GV-+G;-S/Y"CQ\KCQ#
M(3FB>*$H=JXOTOF:OQ'-DE'`88I2E#F,>01&O%P\6CZ0N:^MKA9=B8[)=;#C
ML`)/O+&UQ^]N=6Y&9UGKE5;JKNGOMN;+1:UK@V0-NYS6-<VSW?Z-[&(>#TSJ
M.?G,ZGU$FH,=N9400[V&:V-8[^;IW?V_^W/54&#%[$_=R2C4`>&I<7'(CIPI
MYSF!SF(<M@AD,LIC[G%"6/V81GQ2XI3:WUL_Y1K_`.);_P!58C]?<*>N8619
M+:FBLE\&/98YS^/W6E1^L^)EWY];Z:;+6BH`N8TN$[K-):%L=8Z8WJ6+Z8(9
M:P[JGD=_W'?G;'_R5(,L(1Y;B/IX9PE7Z/'PM>7+9<N3XAP1]8R8<F._ER''
MQRX6^LOZRV,9TBUKC!L<QK!XG<+/^H8Y4L3J/6L&L8M^`^\5-:UCF`\`=WUM
MMKL]NWZ*%;A]6Z[>UV37]CQZMP9N:9$P?H.VV6.=[/?[*E%BY?V\HG.<1C@>
M+C$@>+A]4>&/S-KF.>][EY8L.+(<^:)Q^U*$X>WQ^B?'.7##T.K]7VN;T?'#
M@6F'&#IH7O<T_P!IJT5"JME5;*JQM96T-:.8`&UO*FH/=_7>[7Z?N5_A<3<^
M[G[I]WO7V?9XO^I^WQ/_TO54E\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J
MI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V?_M
M$H90:&]T;W-H;W`@,RXP`#A"24T$)0``````$``````````````````````X
M0DE-`^T``````!``2`````$``0!(`````0`!.$))300F```````.````````
M`````#^````X0DE-!`T```````0```!X.$))3009```````$````'CA"24T#
M\P``````"0```````````0`X0DE-!`H```````$``#A"24TG$```````"@`!
M``````````(X0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F``$`
MH9F:``8```````$`,@````$`6@````8```````$`-0````$`+0````8`````
M``$X0DE-`_@``````'```/____________________________\#Z`````#_
M____________________________`^@`````________________________
M_____P/H`````/____________________________\#Z```.$))300`````
M```"``$X0DE-!`(```````0`````.$))300(```````0`````0```D````)`
M`````#A"24T$'@``````!``````X0DE-!!H``````TD````&````````````
M```V````F@````H`50!N`'0`:0!T`&P`90!D`"T`,0````$`````````````
M`````````````0``````````````F@```#8``````````````````````0``
M```````````````````````0`````0```````&YU;&P````"````!F)O=6YD
M<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<``````````$QE
M9G1L;VYG``````````!"=&]M;&]N9P```#8`````4F=H=&QO;F<```":````
M!G-L:6-E<U9L3',````!3V)J8P````$```````5S;&EC90```!(````'<VQI
M8V5)1&QO;F<`````````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M
M````#$53;&EC94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M
M````"D53;&EC951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0``````
M`%)C=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````
M0G1O;6QO;F<````V`````%)G:'1L;VYG````F@````-U<FQ415A4`````0``
M`````&YU;&Q415A4`````0```````$US9V5415A4`````0``````!F%L=%1A
M9U1%6%0````!```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X
M=%1%6%0````!```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI
M9VX````'9&5F875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!
M;&EG;@````=D969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"
M1T-O;&]R5'EP90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE
M9G1/=71S971L;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR
M:6=H=$]U='-E=&QO;F<``````#A"24T$*```````#`````$_\````````#A"
M24T$%```````!`````(X0DE-!`P`````#+$````!````F@```#8```'0``!A
MX```#)4`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`#8`F@,!(@`"$0$#$0'_W0`$``K_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54E&TV"MYJ:U]@:=C7$M:71[6O>UMCF-W?G^G8N"M_
MQJNQLU^)F])=2ZFTU9&W(#W-+7;+=C?197:YD?Z7W_Z128L&3+?`.+AWU"V>
M2,*XC5O6YGUCZ%@YC,'+SJ:<E\_HWN`VPT6?IW?0Q]S'?H_7=7ZO^"6DO,>N
M?47J_6NL'JG3+F9&!U3]8JR+['`UL<QEC&VL=6VWT_=Z6+757=Z5/I^MZ:Z+
MZR?7&GZI_8NG"I_4;C2"]UMI;9L;%55UMOHV-NLO<R[?_P`7_P`(I9<O$^W'
M%+W,DA<X_NU_T5@RD<1F.&(/I/=ZQ)<?A_7Z[)^KV?UT]-].G!?76QGK@^H]
M[F,M;N]$.J]%MU+_`.;_`$F]9/\`X[W_`)J?_9C_`-]D!R>>5@0OA/"?5'YO
MF_>2<^,5<MQ8T+Z,DO.?_'>_\U/_`+,?^^R7_CO?^:G_`-F/_?9'[CS/[G_.
MA_WR/O&+][\)/HR2\Y_\=[_S4_\`LQ_[[+O>FYGV_IV+G;/3^U4UW>G.[;ZC
M6V;-T-W;=W[JCR\OEQ`&<>&]M8G_`**Z&2$](FZ;*22S?VQ_EC]E^C_UW=_(
M];Z&W^S]-,A"4^+A%\,3.7]V.Z,N;'BX.,\/N3&*&A/%DG\L?2Z2222:R*26
M3U;KW[-R6T>AZNY@?NW[>2YL1L?^XM9/ECG&,92%1G\OC3%CYC%DGDQPE<\)
M`R"B.'B^522228RJ22224__0]57F_P#C1^KC6.9U_&:XFQPJSM21,-9C7[=I
M;6W:ST+/?_W&]GJ66+TA"R<>G*Q[<6]N^F]CJ[621+'C8]NYNUWT7*7!F.+(
M)CRD/WHK,D!.)C]GF^<?4?ZZXO2^@9F'GO;OP6NNP:R=IM#S_16;*W>[[2[=
MO=ZG](_T&,N8Q,;J?UM^L)'N=?F6^ID6-!<VJLD;[/TC_P"8QJ_956ZW_18[
M/S%FYU%>-FY&/5:W(KIM?6R]L;;&M<6-M9M<]NVQHW_37J?^+/I'3\;HQZC5
M95DYF4XMMM8#NJ:-OZD[?[FN:[]+;[*_4WU_SU5>/<M3-P<O&>:`]>7;M9_E
MQM2'%D,<9/I@]`/J_P!*/1&=#LJ]3`8QC#7.PNV%MGJ/=1Z/Z1]K?5M<S^<L
M6=_XWGU/_P#*_P#\&O\`_2RZ-)9(S9!?#.4;-FI$>IN&$3O$&M-0_.B]H_\`
M&\^I_P#Y7_\`@U__`*67BZ^BUI?$<DX>WP2E&^*^$\/[K5Y6,9<5@';</@/6
M\>G%ZSGXM#=E-&3=74R288RQ[&-W.W.^BU>V?5O_`,3O2_\`PGC_`/GIB\7^
MLG_BBZI_X<R/_/KU[1]6_P#Q.]+_`/">/_YZ8F_$-<.+^7Z*>6^>;I+F_P#U
ML?\`7_0+I%Q_5Z;K_K#;302++2Q@(GAU;&OW;?S-G\Y_(5?DH\4LL2:O%,7V
MOA:_Q>9ACY>8CQ&/,XY"(WEPB?I=3(^M6)5=Z==3K6M<6V62`(!C?5&_U?\`
MP-:.!U3#Z@S=0^'B=U3H#P!^=LD^W7Z2G7T_!JJ-+**Q6X`.;M!W;?H>I/\`
M.;?Y:YWJ7I]'ZY5;C;JZGM:^UC8C:7.;;6QI]NUS6?1_?1A#!FN&.,H3`)C(
MGBXZ_>_=1ES<YRG#FSY(9<,I",X1CP'#Q=<<OT_\-U.K=0Z3BY+:\W&]>TL#
M@[TV/ALN&W=8X.^D%JN<UC2]Y#6M$N<=``.22N4^MG_*-?\`Q+?^JL5SZU93
MR*,"J2ZT[WL:#)UVTMT^EN?O]G\A'[L)QY<`D>X)&1.HB(K!SYQ3YZ4HQ(P2
MQQQQB.&6263B`C*7Z23*^M>%6=N/6Z\@CW'V-(C\TN#G_P#@:N]/ZS@YY+:G
M%E@,"NR`XZ;MS`'.WJ?3>EXO3Z@VMH=;'ON(]SIY_JL]O\VL;ZQ=+JQFLS\-
MII<US0]M8AH_<N;M_FO<W:A&/+9)>U$2B3I#(3Q<4OZT%V3)\0P8_O&26/)$
M>K+R\8\'MP_U>7]+A>E25?`RAEX5.0(FQH+H!`#A[;&C=^Z_<K"J\$N/@KU7
MPU_6V='W8>U[M_J^'W.+^I7'Q/\`_]'U5<G_`(POK+^R.E'$Q+O3ZEF0&;'1
M975_A<CZ+MN[;Z%?\T_W^K1_1UU5MC:JWV.#BUC2XAK2]T`3[*ZPZRQW\AC5
MXWUS"^MGUBZR_,MZ5EUNO<VNFIU=@96P>RNOU;FMKK;_`(2VS]%5ZGJW?HU:
MY/%&>3BF0(0UUZGH&'/,QC4;XI::-3H?U4ZCUO!S\W%T9@LEC2UQ-UGTW8]&
MQKOTGI-_[<?CU_X?U:[_`-0?K0[HO4QBY+W?L[,<&/:7`,KL<6M9EGU/:UK6
M^R_WU_HOTGZ3T*F+U/H?1L7HO3*>GXS6@5M!ML`@V60/5O?)>[=8X?O_`*/^
M:_FZUYK]=_J9FXO677='P;;<+*;ZC68U;GMJ>/;=5MK]1S&[OTU?MJK_`$OH
MT_S"MPYF',2R8IZ0E_-WX?\`=?IL,L4L8C./S#YGUE)<M]0>H=5LZ8.F]6Q,
MC&OPFAM%EM#ZF/H:&LK9ZKFBMU]/T/S-]7I_SOZ=ZZE9N2!A,Q)NNHZMJ,N(
M`]WYT7T6O!?^;?UB_P#*O,_]A[?_`""]Z5[XG*)]NB#\VW^"U^4!''8K9\%^
MLG_BBZI_X<R/_/KU[1]6_P#Q.]+_`/">/_YZ8O)OK!]7^O7=>ZE;5TW+LKLR
M[W,>VBPM<TV/<U['-9M<US50_P";?UB_\J\S_P!A[?\`R"GS8H9\>./N"'"`
M?WNG]YCA.6.4CPDV^]+FG.:WZX2XAHD"3IJ:=K1_:<O*O^;?UB_\J\S_`-A[
M?_(+LOJQT3K'V/%I=CVXEH+SOM8^O:0Y]C2YVS<S^0H\?*X\0R$YHGBA*':N
M+]+YFK\1S9)1P&&*4I0YC'D$1KQ</%H^D+FOK:X678F.R76PX[`"3[RQM<?O
M;G5N1F=9ZY56ZJ[I[[;FRT6M:X-D#;N<UC7-L]W^C>QB'@],ZCGYS.I]1)J#
M';F5$$.]AFMC6._FZ=W]O_MSU5!@Q>Q/W<DHU`'AJ7%QR(Z<*><Y@<YB'+8(
M9#+*8^YQ0EC]F$9\4N*4VM];/^4:_P#B6_\`56(_7W"GKF%D62VIHK)?!CV6
M.<_C]UI4?K/B9=^?6^FFRUHJ`+F-+A.ZS26A;'6.F-ZEB^F"&6L.ZIY'?]QW
MYVQ_\E2#+"$>6XCZ>&<)5^CQ\+7ERV7+D^(<$?6,F')COY<AQ\<N%OK+^LMC
M&=(M:XP;',:P>)W"S_J&.5+$ZCUK!K&+?@/O%36M8Y@/`'=];;:[/;M^BA6X
M?5NNWM=DU_8\>K<&;FF1,'Z#MMECG>SW^RI18N7]O*)SG$8X'BXQ('BX?5'A
MC\S:YCGO>Y>6+#BR'/FB<?M2A.'M\?HGQSEPP]#J_5]KF]'QPX%IAQ@Z:%[W
M-/\`::M%0JK956RJL;65M#6CF`!M;RIJ#W?UWNU^G[E?X7$W/NY^Z?=[U]GV
M>+_J?M\3_]+U5)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JD
ME\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]D`.$))300A````
M``!3`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````
M$@!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P````$`.$))
M300&```````'``0````!`0#_X1?Y:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+P`\/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E
M4WI.5&-Z:V,Y9"<_/@H\>#IX;7!M971A('AM;&YS.G@])V%D;V)E.FYS.FUE
M=&$O)R!X.GAM<'1K/2=835`@=&]O;&MI="`S+C`M,C@L(&9R86UE=V]R:R`Q
M+C8G/@H\<F1F.E)$1B!X;6QN<SIR9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y
M.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N
M861O8F4N8V]M+VE8+S$N,"\G/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2=U=6ED.F$P9CEE93,T+3<T.3,M,3%D9"TY.3ED+6)F93=C-S,S.&(Y
M9"<*("!X;6QN<SIE>&EF/2=H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP
M+R<^"B`@/&5X:68Z0V]L;W)3<&%C93XQ/"]E>&EF.D-O;&]R4W!A8V4^"B`@
M/&5X:68Z4&EX96Q81&EM96YS:6]N/C$U-#PO97AI9CI0:7AE;%A$:6UE;G-I
M;VX^"B`@/&5X:68Z4&EX96Q91&EM96YS:6]N/C4T/"]E>&EF.E!I>&5L641I
M;65N<VEO;CX*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2=U=6ED.F$P9CEE93,T+3<T.3,M,3%D9"TY.3ED+6)F
M93=C-S,S.&(Y9"<*("!X;6QN<SIP9&8])VAT='`Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\G/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70])W5U:60Z83!F.65E,S0M-S0Y,RTQ,61D+3DY.60M
M8F9E-V,W,S,X8CED)PH@('AM;&YS.G!H;W1O<VAO<#TG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R<^"B`@/'!H;W1O<VAO<#I(:7-T;W)Y
M/CPO<&AO=&]S:&]P.DAI<W1O<GD^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA,&8Y964S-"TW-#DS
M+3$Q9&0M.3DY9"UB9F4W8S<S,SAB.60G"B`@>&UL;G,Z=&EF9CTG:'1T<#HO
M+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\G/@H@(#QT:69F.D]R:65N=&%T:6]N
M/C$\+W1I9F8Z3W)I96YT871I;VX^"B`@/'1I9F8Z6%)E<V]L=71I;VX^-S(O
M,3PO=&EF9CI84F5S;VQU=&EO;CX*("`\=&EF9CI94F5S;VQU=&EO;CXW,B\Q
M/"]T:69F.EE297-O;'5T:6]N/@H@(#QT:69F.E)E<V]L=71I;VY5;FET/C(\
M+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA,&8Y964S-"TW-#DS
M+3$Q9&0M.3DY9"UB9F4W8S<S,SAB.60G"B`@>&UL;G,Z>&%P/2=H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O)SX*("`\>&%P.D-R96%T941A=&4^,C`P
M."TP."TR-U0Q.3HU-3HU,"TP-3HP,#PO>&%P.D-R96%T941A=&4^"B`@/'AA
M<#I-;V1I9GE$871E/C(P,#@M,#@M,C=4,3DZ-34Z-3`M,#4Z,#`\+WAA<#I-
M;V1I9GE$871E/@H@(#QX87`Z365T861A=&%$871E/C(P,#@M,#@M,C=4,3DZ
M-34Z-3`M,#4Z,#`\+WAA<#I-971A9&%T841A=&4^"B`@/'AA<#I#<F5A=&]R
M5&]O;#Y!9&]B92!0:&]T;W-H;W`@0U,@5VEN9&]W<SPO>&%P.D-R96%T;W)4
M;V]L/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70])W5U:60Z83!F.65E,S0M-S0Y,RTQ,61D+3DY.60M8F9E-V,W
M,S,X8CED)PH@('AM;&YS.GAA<$U-/2=H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O;6TO)SX*("`\>&%P34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP
M:&]T;W-H;W`Z83!F.65E,S,M-S0Y,RTQ,61D+3DY.60M8F9E-V,W,S,X8CED
M/"]X87!-33I$;V-U;65N=$E$/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z83!F.65E,S0M-S0Y,RTQ
M,61D+3DY.60M8F9E-V,W,S,X8CED)PH@('AM;&YS.F1C/2=H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R<^"B`@/&1C.F9O<FUA=#YI;6%G92]J
M<&5G/"]D8SIF;W)M870^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F.E)$
M1CX*/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^_^(,6$E#0U]0
M4D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`,0``
M86-S<$U31E0`````245#('-21T(``````````````````/;6``$`````TRU(
M4"`@````````````````````````````````````````````````````````
M```````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````48FMP
M=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D`````4
M9&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P```]0`
M```D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E120P``
M!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`````
M````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V,3DV
M-BTR+C$`````````````````````````````````````````````````````
M`````````````%A96B````````#S40`!`````1;,6%E:(```````````````
M``````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:
M6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO+W=W
M=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````
M````````````````````````````````````````````````````````9&5S
M8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="`````````````````````````````&1E
M<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V
M,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ``````````````````````````````````!V
M:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@``````!,
M"58`4````%<?YVUE87,``````````0````````````````````````*/````
M`G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`*``M
M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`
MGP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3
M`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!
ML0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q
M`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#
M9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^
M!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%
MU07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/
M!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)
M$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS
M"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-
M)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z
M#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2
M)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P
M%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8
M&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC
M&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?
M$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=
M(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G
M&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI
M*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP
M-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43
M-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z
M=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B
M0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%
MWD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB
M3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2
M?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:
M66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@
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MB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1
MJ)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5
MFT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:D
MQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZA
MKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y
M2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4
MQ%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/
M-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IV
MVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WF
MEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,
M\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_
M;?___^X`#D%D;V)E`&0``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+
M#`H*"PH*#!`,#`P,#`P0#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$'
M!P<-#`T8$!`8%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`-@":`P$1``(1`0,1`?_=``0`%/_$
M`:(````'`0$!`0$```````````0%`P(&`0`'"`D*"P$``@(#`0$!`0$`````
M`````0`"`P0%!@<("0H+$``"`0,#`@0"!@<#!`(&`G,!`@,1!``%(1(Q05$&
M$V$B<8$4,I&A!Q6Q0B/!4M'A,Q9B\"1R@O$E0S13DJ*R8W/"-40GDZ.S-A=4
M9'3#TN(()H,)"A@9A)1%1J2T5M-5*!KRX_/$U.3T976%E:6UQ=7E]69VAI:F
MML;6YO8W1U=G=X>7I[?'U^?W.$A8:'B(F*BXR-CH^"DY25EI>8F9J;G)V>GY
M*CI*6FIZBIJJNLK:ZOH1``("`0(#!04$!08$"`,#;0$``A$#!"$2,4$%41-A
M(@9Q@9$RH;'P%,'1X2-"%5)B<O$S)#1#@A:24R6B8[+"!W/2->)$@Q=4DP@)
M"A@9)C9%&B=D=%4W\J.SPR@IT^/SA)2DM,34Y/1E=865I;7%U>7U1E9F=H:6
MIK;&UN;V1U=G=X>7I[?'U^?W.$A8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ
M.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`]4XJ[%6.ZQ^8OD71M8AT;5-<
ML[/4IN7[B64#T^*"3]^WV+?DC*8_7:/U?]U<\R<>DRSCQ1C(Q_'T_P`[_-:I
M9H1-$[LBS&;78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_]#U+<M<
M+;RM;(DMR$8P1RN8T9P/A5W59&12WVG$<G'^1L(J]^2"\&N?^<JI-/UF73-7
M\I/:R6=RUMJ`BOTF>(Q2<)>"B%(Y62C<1ZJH_P#OS]K-\.P^*/%&=V.*/I_X
M\ZX]H4:,?M2#SS^1?F[S?YP;S+Y=O(;_`$'S)2_MM0O9W5X(I($D194:-95C
M8MZ5K'%',T4*QI-Z?',C3=IX\./@F.&>/T\,1]6_XX_]BUY=)*<N*.\9_C_I
M%Z-^9/YQ6?Y8?H;0$M)M?O39AII+FY:.<11TBBFEE]&19I)V2;G3BW*/DR_O
M%S6Z/L\ZGBG?ACBZ#_CWIX7*SZD8JC]2&T?\_;S4/R^U_P`Z/Y:]"RT::WMX
M8OKJO]8EFD1)5Y>B&B]%9H7J8W63GQ7[+9/)V4(YHXN/>=_P_3_LOXN%$=83
M`SX?I\V*?]#>?]^G_P!S#_LVS*_D#^G_`+#_`(^T_P`I?T?M_8[_`*&\_P"_
M3_[F'_9MC_(']/\`V'_'U_E+^C]O['?]#>?]^G_W,/\`LVQ_D#^G_L/^/K_*
M7]'[?V._Z&\_[]/_`+F'_9MC_(']/_8?\?7^4OZ/V_L>\^6]8_37EW2]9]'Z
MO^DK."\]#ES]/UXEDX<J+RX\J<N*YH<V/@F8_P`V1C_I78PEQ1![TQRMDQS_
M`!A_SN/^'/JG_1UZG_%'K?8X_P"Q^WFQ_D__``;QN+_,K^GP?5;H?Y;_`,/_
M`"G!_P`E.+_:O&^CA_S?K9'FN=\[%6)^;//G^']1CLOJ/UGU(5F]3U?3IR9E
MI3@_\F;70]F?F(&7%P^KA^GB_P!\\SVS[1?DLHQ^'XG%#CXN/@_BE'^9/^8R
MS-4],[%78J[%78J__]'U3BKYP_YRB_+J.*2'SSIT3EIW2VUP`NX!"*EM/QXE
M8UXIZ$C%U3G]6X)ZDDC-T?8FKO\`='WP_P!]'_??Z9U>OP_QC_.0_P"2'YU:
M5Y<\@ZQI6MS)ZVBH]WHEN[<#<B8DFU0I&WQ?66Y<V,C\+AWX>A;/QGVEV=+)
MEC*/\?IG_1_I_P"D_P!S_.FC2ZH1@0?X?I>8Z3IOF7\T/S"8'G)?:M<F>_N$
M#2):VY<!Y*2/M!;1E4BC:7]F*W1N;)FSR3AI</E`>G^G+_BI?\><2,999^<G
MV&/R_P#*S>2H?)D]IZ^@Q0Q0M`6,32>BZR"1V@]$^H\J^K*R</4DY?S9Q_YO
M)XOB@^O\?SG=^#'@X/X6.?\`0O7Y/_\`5@_Z>[W_`*KYD?RMJ?YW^QA_Q+5^
M3Q=W^Z?%^=HZ)]H?]"]?D_\`]6#_`*>[W_JOG%_RMJ?YW^QA_P`2[W\GB[O]
MT^2?.VG6>F^<]?TZRC]*RLM1N[>VBJS<(HIW1%Y,69N*J!5CRSK=-,RQ1D><
MHQ^YTV6($R!WOMG\M_\`R7?E;_MD6'_4-'G%:S^^G_7E_NG?8/HC_5#(LQFU
MYS_Y6+_/_EASHO\`G7?C_57@O^=]^/\`E%1^H_FKI-M>_5[>UDN8HY&CGG#(
M%XJU.<5"_J@[E:F/]G*,78F24;)$37IC_P`7_,_V3G:GVQP8\G#&$LD8R,9S
MN/\`"?KQ?7XO_2O^%D.@>:-(UR'G92TE'+G:R<5F4*0.10$_#NOQ+\/^RS7Z
MK19,!J0V_G?P.\[-[7P:R-XSZO\`4Y?WL?\`,_F_TH^G_.2GS9Y@\J:=J,<&
MKZ;]<N6A5TE]"&6B%F`7E(P;[0;;,K0Z349($XY\$>+^=*/^Y=9VSVGHL&41
MSXO%GP<7%X>/)Z.*7I_>2_K,JEECBC>65Q'%&"SNQ`55`J22>@&:L`DT.;TD
MYB(,I'AC%A6J?FMHUNQ2PMY+Y@1\9_<QE2*DJ6#/4'X:-&N;K#V'DEO,B'^S
ME_Q/^R>2U?MCIX&L499O^E4/]]/_`*5Q3OR_YST/7&:.VD,-P#1;:?BDCBG+
MD@#-S&S5XGX?VLPM5V?EP;R%Q_G1^EVW9O;NFUAJ!X9_ZGDX8SE_4]4N/_>_
MQ)YF"[EV*O\`_]+U3BJ'U+3K/4M.NM.O8_5LKV&2WN8JLO.*52CKR4JR\E8B
MJGEDH3,9"0YQ1*((HOS_`-;L+?3]9O["VNTO[:TN9H(+Z*G"=(I"BRIQ9UXR
M*.:T=_\`6SO\<C*()'"2/I_FO-S%$CF^I?\`G&;REY>T_P`G'7[:XMM0UC4G
M9+JYB#<[9%XGZDW.C*RL/5EHD?J<X_[Z*.WF;E^V<\Y9.`@QC'_9?[9^/]CZ
MG;Z''$1XN9/XX7L>:9SG8J_.K/17F'Z*YYT].^#?S(_\F)YI_P"VO?\`_43)
MG>:/^YA_4C_N7G<_UR_K%]H?EO\`^2[\K?\`;(L/^H:/.,UG]]/^O+_=.]P?
M1'^J&19C-KR#S=:7MY^85S9V1(N+DQ0J5Y"BO;HK\N()X<"WJ?Y'+.NT&2,-
M()2^F/%+_9G_`&7\W^D^7=M8<F7M26/']>3@AU_CPPC/BX?X.#B\3^AQ/4+?
M0-#M[5K2&P@6WD"++&8U(<1_8]2H/J%>O)^6<S/5992XC*7%[_IXOYO\U]$Q
M=FZ:$#"..'!*N*/#'U\'T>)_JG^>\Z\Q_5O*GGBVNM.YV]M*B374$5""CR,L
ML:*:+Q94JJG[+_8X<4X]#I.+5:4QGZI"XQD?ZOHE_LGA.U.#LWM&,\5PA(1R
M9(0_F2G+Q<<(_P`V7!Z8_P`,_HX.&'"G^;/_`"D=M_S!I_R=DR787]R?Z_\`
MO8M?MG_C<?\`A4?]WD3C\U-4G9;+1+4EI;D^K-"@<NPKQA44V8,_/X/B^-$S
M#[$PCU99<H^D?[_\?TI.U]L-7(B&FAO+)ZYPCQ<4OX<,?Z7%/C]'J]<(,H\N
M>5M,T*U6.W0275")KQE'J.30D5WXI\(XQU_X)_BS6:O6SSRL_3_##^'_`*2_
MI/1=E]D8='`"(XLG\>7^.?\`Q,/]K_W4_4P[\Q?*UKIT<.N:4AM721$FC@7B
MB&AX3+QIZ1#*J[?:9D_;^WM^R=;+(3BR>K;^+_<?T_Q_F\M[3]D0P`:G`/#(
ME&,XX_3"/\S-Z?[KU<,?Z4I0_C^N=:!JBZIHUG?@@M/&#+Q!51(/AD4!MZ*X
M9<TFJP^%DE#^:?\`8_P_[%['LW5C4:>&7^?'U?U_\I]7\V?$C\QW-?_3]4XJ
M\I_YR#_,O_"OE8Z7I=YZ'F35J)#Z3\9X+6I]6X'PMQY<?0C;E$_)VE@?G;MF
MU[)T?BY.*0_=P_V4OYO^^_W7U.'K,_!&@?5)\Z>1_P`JO,7G#0M=UC3OABT:
M'G%$8Y7:[G`YM;P<%8-(L2EN(Y-ZCV\?#C/ZL?1ZG70PSC&7\?\`L/Z4OQ_.
M_FNKQ:>4P2/X4^_(/\T)/*'F5=-U&9_\.ZNZQ3HTB)%;W#LJI=GU**JJHX3T
M>/\`=?O']3T(DS'[4T7C0XA_>0_V4?YG_$_\>;='GX)4?IE^.)]AYQ[NW8J_
M.K/17F'Z*YYT].^#?S(_\F)YI_[:]_\`]1,F=YH_[F']2/\`N7G<_P!<OZQ?
M:'Y;_P#DN_*W_;(L/^H:/.,UG]]/^O+_`'3O<'T1_JAD68S:\VDECC_.`-(X
M1254%B`.3V851OW9B%7.C`)[.V_'[UX&4Q'MZR:_X]IN&/\`II/2<YQ[YYM^
M;4BSWNDV,(,EV!(WHJI+$2LBQTH/B+-&PXC.C["'#&<CM';_`&%\7^Z>!]LY
M">3%CCZLGJ]'_#3"./\`TTL<D!^;/_*1VW_,&G_)V3,CL+^Y/]?_`'L7!]L_
M\;C_`,*C_N\B/\_2+:^>-%OK@%+2,0,\W$E:17#,]*`U*J02HS'[+'%I<D1]
M1XO]E#TN=[1R&/M'#DEMCCX?K_X7EE*?^EB])SG'OF,?F3<0Q>4KJ.1N+W#Q
M1PBA/)A()*;=/@1COFS['@3J`1_#Q?[GA_WSSOM5EC'0R!YS,(Q_K<8R?[B$
ME;\OXI(_*&G+(A1B)&`8$'B\KLIW[,I#+D.U2#J)5Y?[D-WLU`QT&,$5]7^R
MR3E'_319#FO=X__4]2W-Q';V\MQ(':.%&D=8D>5R%%2$CC#22-M\*(K.W[.$
M"S2":?''G?1OS8\^^<9M6N?*NJ6\EX\<%G:O;W(AMXA1(X_5F58XUW]260^E
M%ZCRS<8^6=CILFGP8^$3AM]6\?5_I71Y8Y,DKX2^K?(_D[2O*'EJST/3D0+`
MBFZN$7@;BX*@2SN"SMRD8="[>FG")/W<:9RNIU$LTS,_](Q_FNYQ8A"-!\V?
MG;^3.LZ;YQ>[\J:'<W6B:F@GC@T^WDE2VF'PS1<8S(R*6I-'\,4?[WT85XP9
MTG9O:,98ZR2`G'^>?J_'_27U.JU6E(E<1Z3_`#7K_P"0?F#S5-Y:7R]YHTF^
MT^^TA%BL+BYL9K:*6R152-/591&T\/V"OP,\7IO^]=9WS3]J8L8GQXY1D)_5
MPRXO7_Q/X_FN;HYRX>&0(,?+^%ZEFK<Q\&_\JW_,3_J5M7_Z0+G_`*IYWGYS
M#_/A_IHO.^!/^;+Y/O+.#>B?%?G_`,@>>[KSWYDN;;RWJD]M/JE[+!/%97#H
MZ/<.RNC*A5E9356&=KI=5B&*`,X7P1_BC_-=#FPS,SL>9Z)#_P`JW_,3_J5M
M7_Z0+G_JGE_YS#_/A_IHM?@3_FR^3O\`E6_YB?\`4K:O_P!(%S_U3Q_.8?Y\
M/]-%?`G_`#9?)[)^6'DGS>-&TNTDT^ZTR[4RL)KJ&>W$3+*\BEF*<D)H.'^Q
MRK/K\$8$F49C^;$QEQ?YKR6K[)U6;7'@C+']/#FD)PQQX,8_RD8_T?3_`$WJ
M,/G'SQ;6TEM=^7IKB]CJBW*1R!"5'$,RHK+)\0Y$QNB-^QQS32[/TLI"4<L8
MP_FW']?I_P`Z,G=8^W.T<<#">GGDRQ]/B1C/@_K2C",HY/5ZOW<X0E_!PJ&A
M>6/,6M:Y#YBUYC;+%()(;8@K)^Z8&-%1A^[AY?S?&W_/3U<GJ=;APXCAQ>JQ
M]7\/K^KU?Q3_`-C_`*7@:>S^R=5J]3'5ZD^'PRXHX_IG^[E^[AP2_N\/%_GR
M_P"2GBH;\SM(U:\UZWEL[*>YB%JBEX8G=0PDD-*J#OOEO8V?'#$1*48GC_B/
M]&+1[6:+/EU,98X3R1\*/T0E/^/)_-9CYO\`+$?F#3/0#"*[A/J6LQ`(#4H4
M8T+!'_:X_P"0WQ<>.:?0:TX)WSB?J_'\YZGMOLD:W#PWPY(>K'+_`'DOXN"?
M\7#_`$)>KAX6,Z5YB\ZZ-;+IM[H$UZ+5$CADA5A10-@7C66.2B\5^'C]GX^3
MYLL^DTV:7'')&'%]7%_Q,N"47G]'VIVAI(##DT\\WAB,82AQ?3_7QQRX\GIX
M8^G^;Z^*:&N=(\V>=+^.34;?]$Z=;>H(O4C/)>5#]ABLDC-\`+_!%\'P_%\+
M60U&GT<"('Q9RKK^(Q_V4VC+HM=VME!RQ_*X<?%P\4?5_I)<.3)*7H]?HQ>C
MT^KTRZ/;6\-M;16T"\(8$6.)*DT5!Q45-3T&<[.9E(R/.3WF+%''`0CM&`$8
M_P!6*ID6Q__5]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
%J[%7_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
